Oral Drug Could Help Manage A1C in Patients with Type 1 Diabetes

Posted in Diabetes Research News

A major challenge for individuals living with type 1 diabetes (T1D) is reaching target A1C levels. Despite careful management of the disease and regularly checking blood sugar, many people’s A1C is still higher than recommended. While individuals with type 2 diabetes have a variety of medications they can take to help manage blood sugar, those with T1D must rely on insulin.

However, that may be changing. While insulin would still be necessary, a new oral drug may help individuals with T1D to achieve target A1C levels. The drug – sotagliflozin—prevents the kidneys from reabsorbing sugar and delays the absorption of glucose in the gastrointestinal tract. This means that there is less sugar in the blood because more of it is lost through urine output. According to researchers, there was a “two-fold increase in the number of patients who reached the target A1C level while on the drug.”

In addition to achieving improved A1C levels, many participants also experienced weight loss and a decrease in the amount of insulin needed to manage their T1D. This is a major breakthrough for patients with T1D as it would be the first ever oral antidiabetic drug for the disease in the United States. Three clinical trials encompassing 3,000 participants have been conducted so far to test safety and efficacy, and the drug is slated for a vote by the FDA for approval.

The Diabetes Research Connection (DRC) is excited to continue following this study and the potential approval of sotagliflozin as another option in the treatment of type 1 diabetes. It would give patients another resource for helping to manage this disease and its impact on their health. The DRC is committed to supporting research that improves the diagnosis, treatment, and prevention of type 1 diabetes and enhances quality of life for those living with the disease. Learn more about current projects and how to contribute to critical funding by visiting http://diabetesresearchconnection.org.